Study investigates the link between COVID-19 vaccines and autoimmune/neurological diseases, focusing on Guillain-Barre syndrome (GBS) risks associated with adenovirus vector vaccines.
Study finds the JN.1 variant of SARS-CoV-2 may not have increased immune escape ability compared to its predecessor BA.2.86, suggesting other factors for its rapid spread.
Study reveals robust memory T-cell responses to SARS-CoV-2 in healthcare workers over 1.5 years post-Omicron, suggesting durable immunity against highly mutated variants.
Researchers engineered IgA antibodies from IgG monoclonals, enhancing neutralization against Omicron by up to 75-fold and offering protection in mice models.
Study reveals that the Omicron subvariants BA.2.86 and FLip show unique mutations and infectivity profiles, with BA.2.86 being highly infectious and resistant to most conventional antibodies, underscoring the need for updated vaccines.